How to pronounce Xalkori?

Q: How to pronounce Xalkori?

Xalkori is pronounced “zal-KOR-ee”. Xalkori is the brand name product for crizotinib (pronounced “kriz OH ti nib”), the generic name of the drug.

Official answer

by Drugs.com

Xalkori is pronounced “zal-KOR-ee”. You can also listen to the pronunciation here.

Xalkori is the brand name product for crizotinib (pronounced “kriz OH ti nib”), the generic name of the drug.

Xalkori was first approved in August 2011 and is manufactured by Pfizer Oncology.

Xalkori is a cancer medicine that you take by mouth.

Does Xalkori treat lung cancer?

Yes, Xalkori is a prescription medicine approved by the FDA to treat three types of cancers: non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), a type of blood cancer, and anaplastic lymphoma kinase (ALK)-positive inflammatory myofibroblastic tumors (IMT), a type of solid tumor.

Non-small cell lung cancer (NSCLC)

Xalkori is an oral anaplastic lymphoma kinase (ALK) inhibitor used for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ALK and ROS-1 are abnormal genes that cause the cell to multiply out of control, resulting in cancer growth.

Most lung cancers (80% to 85%) are classified as non-small cell lung cancer (NSCLC).

The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes start from different types of lung cells, but are grouped under NSCLC as treatment and outlook are often similar.

Anaplastic large cell lymphoma (ALCL)

Xalkori is also used in children 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. It is not known if Xalkori is safe and effective in older adults with relapsed or refractory, systemic ALK-positive ALCL.

Anaplastic large cell lymphoma is a rare form of non-Hodgkin lymphoma (NHL), a type of lymph cancer, and accounts for approximately 30% of cases of NHL in young people.

It develops when T-cells, a type of white blood cell that fights infection, become abnormal.

About 90% of ALCL cases in young people are ALK-positive.

ALK+ inflammatory myofibroblastic tumors (IMT)

In July 2022, the FDA approved Xalkori for the treatment of anaplastic lymphoma kinase (ALK)-positive inflammatory myofibroblastic tumors (IMT) for adult and pediatric patients 1 year of age and older. This indication is for patients with tumors that cannot be surgically removed, have returned, or when a different treatment does not work or is no longer working.

IMT is rare type of cancer that is made up of cells from smooth muscle, connective tissue cells, and some types of immune cells.

It usually occurs in the lungs, in the abdomen (stomach area) or back of the abdomen, or pelvis but can occur anywhere in the body.

This is not all the information you need to know about Xalkori (crizotinib) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Xalkori information here, and discuss this information and any questions you have with your doctor or other health care provider.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.